Drug intelligence / Profile preview

LXH-2301

Development stage: Unknown
Lead developer: Jiangsu Nuohe Bituo
Modality: Small Molecules
Administration: Oral

Overview

LXH-2301 is an orally bioavailable small molecule inhibitor of the urate transporter 1 (URAT1), developed by Jiangsu Nuohobito New Drug Research and Development Co., Ltd. It is currently in clinical development for the treatment of hyperuricemia and gout. The drug works by selectively targeting URAT1, a transporter protein located in the proximal tubules of the kidney that is responsible for the reabsorption of uric acid from the urine back into the bloodstream. By inhibiting this process, LXH-2301 increases the renal excretion of uric acid, thereby lowering serum uric acid levels and preventing the formation of urate crystals associated with gouty arthritis.

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on LXH-2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LXH-2301.

Explore the full profile